Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
BRAF and lung cancer are reported together in 7 articles.
Gene
BRAF
- HGNC
- HGNC:1097
154articles
154mentions
3variants with confirmed gene link
Most co-reported phenotypes (articles)
thyroid cancer 54colorectal cancer 29lung cancer 7breast cancer 6ovarian cancer 4cardiomyopathy 2epilepsy 2Down syndrome 1
Reported variants (articles · ClinVar status)
Phenotype
Lung cancer
398articles
398mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
7 records shown · first 60CRISPR-Edited Cell Lines: A New Era in Functional Oncology Research.
PMID 40814875 | DOI 10.2174/0113816128413220250728182852 · Current pharmaceutical design · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of epithelial-mesenchymal transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “As a result of these innovations, it is now possible to track how cancers like non-small cell lung cancer (NSCLC) and ovarian cancer evolve, change their epigenetic features, and find strategies to reverse their resistance.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | MED12 | “Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of epithelial-mesenchymal transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Some of the key improvements are in the use of Mediator Complex Subunit 12 (MED12)-knockout cells to study cell resistance to BRAF inhibitors, CRISPR models of epithelial-mesenchymal transition for breast cancer, and pharmacogenomic analysis in various cancer cell lines.” | 0.98 | phenotype_alias_lexicon_v2 |
Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.
PMID 40927306 | PMCID PMC12416486 | DOI 10.36401/JIPO-24-35 · Journal of immunotherapy and precision oncology · 2025 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2 mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ALK | “This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2 mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region.” | 0.98 | hgnc_dict_v1 |
| gene | EGFR | “This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2 mutations in patients with NSCLC within the Middle East and North Africa (MENA) region and to assess the current state of molecular testing and targeted treatments in the Gulf Cooperation Council (GCC) region.” | 0.98 | hgnc_dict_v1 |
Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.
PMID 37576670 | PMCID PMC10413849 | DOI 10.1021/acsomega.3c00332 · ACS omega · 2023 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Cancers caused by these include melanoma, thyroid cancer, ovarian cancer, colorectal cancer, nonsmall cell lung cancer, and others.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | colorectal cancer | “Cancers caused by these include melanoma, thyroid cancer, ovarian cancer, colorectal cancer, nonsmall cell lung cancer, and others.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | thyroid cancer | “Cancers caused by these include melanoma, thyroid cancer, ovarian cancer, colorectal cancer, nonsmall cell lung cancer, and others.” | 0.98 | phenotype_alias_lexicon_v2 |
Utility of Single-Gene Testing in Cancer Specimens.
PMID 36150818 | DOI 10.1016/j.cll.2022.05.001 · Clinics in laboratory medicine · 2022 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “One of the most common strategies is single-gene testing, which is often conducted for known mutations, such as BRAF in melanoma and EGFR in lung cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “One of the most common strategies is single-gene testing, which is often conducted for known mutations, such as BRAF in melanoma and EGFR in lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “One of the most common strategies is single-gene testing, which is often conducted for known mutations, such as BRAF in melanoma and EGFR in lung cancer.” | 0.98 | hgnc_dict_v1 |
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
PMID 33956842 | PMCID PMC8101740 | DOI 10.1371/journal.pone.0251080 · PloS one · 2021 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “851 cases of non-small cell lung cancer cases were profiled for the presence of biomarkers EGFR, KRAS, BRAF, and PIK3CA mutations by SNaPshot/sizing genotyping.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.” | 0.98 | hgnc_dict_v1 |
| gene | ROS1 | “EGFR, ALK, ROS1) and checkpoint inhibitors such anti-PD-1 and PD-L1 immunotherapies are being used to treat lung cancer patients.” | 0.98 | hgnc_dict_v1 |
Molecular profiling of non-small cell lung cancer.
PMID 32756609 | PMCID PMC7406040 | DOI 10.1371/journal.pone.0236580 · PloS one · 2020 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “Molecular profiling of non-small cell lung cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
| gene | KRAS | “833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK.” | 0.98 | hgnc_dict_v1 |
KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
PMID 26146959 | PMCID PMC6289253 | DOI 10.1038/labinvest.2015.90 · Laboratory investigation; a journal of technical methods and pathology · 2015 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | BRAF | “The expression of SPRY1, a negative regulator of receptor tyrosine kinase (RTK) signaling, was analyzed in both KRAS(G12D)-and BRAF(V600E)-induced thyroid cancers.” | 0.98 | hgnc_dict_v1 |
| phenotype | lung cancer | “KRAS(G12D) can cause lung cancer rapidly, but is not sufficient to induce thyroid cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | KRAS | “KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.” | 0.98 | hgnc_dict_v1 |
| gene | SPRY1 | “KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.” | 0.98 | hgnc_dict_v1 |